Clovis Oncology, Inc.: directors' dealings · United States · SEC (Form 4)

About Clovis Oncology, Inc.

Clovis Oncology, Inc. was a U.S.-based biopharmaceutical company focused on oncology precision medicine and historically listed on the NASDAQ market in the United States. Founded in 2009 and long headquartered in Boulder, Colorado, the company built its business model around acquiring, developing, and commercializing anti-cancer therapies aimed at well-defined patient subgroups, often in combination with companion diagnostics. Its best-known commercial asset was Rubraca® (rucaparib), an oral PARP inhibitor used in specific oncology indications, including certain ovarian cancer settings and, at one point, metastatic castration-resistant prostate cancer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1466301/000156459016013672/clvs-10k_20151231.htm?utm_source=openai)) From an industry perspective, Clovis belonged to the specialized biotech segment, where value creation depends on clinical differentiation, regulatory execution, and the ability to serve niche oncology populations. The company’s legacy footprint extended beyond the United States, with operations and additional offices in Europe, including Cambridge in the United Kingdom and Milan, Italy. That international setup reflected its ambition to develop and commercialize oncology assets across the U.S., Europe, and other markets. Its competitive set included other PARP inhibitor developers, targeted oncology biotechs, and larger pharmaceutical groups active in precision cancer care. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1466301/000156459016013672/clvs-10k_20151231.htm?utm_source=openai)) Clovis’s corporate trajectory is also defined by financial stress and restructuring. The company and certain subsidiaries filed voluntary Chapter 11 petitions in December 2022 in the U.S. Bankruptcy Court for the District of Delaware. The court later confirmed the company’s Third Amended Joint Chapter 11 Plan of Liquidation in June 2023, with an effective date of July 10, 2023. For equity investors, that is a critical point: the company’s public-market story is no longer one of normal growth execution, but of restructuring and asset disposition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1466301/000119312522303179/d386858dex991.htm?utm_source=openai)) In analytical terms, Clovis was a classic high-risk oncology biotech: concentrated product exposure, heavy clinical and regulatory dependence, and significant financing vulnerability. The most recent material developments therefore center on bankruptcy proceedings and asset sales rather than product launches or commercial acceleration. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1466301/000119312523094018/d492602d8k.htm?utm_source=openai))